STATED PURITY ≥99% Retatrutide
Triple Agonist · MW: 4731.3 Da
Triple agonist peptide targeting GLP-1, GIP, and glucagon receptors. Research-grade compound studied for metabolic and body composition applications. Stated purity ≥99%.
Volume savings
| Quantity | Per unit | Total |
|---|---|---|
| $59.99 | $59.99 | |
| $56.99 | $113.98 | |
| $53.99 | $161.97 | |
| $47.99 | $239.96 |
Discounts apply per product and size, based on the quantity of that item in your order. They are applied automatically in your cart.
This item is currently out of stock. Email support@sealedpeptides.com and we will let you know when it is back.
US only · Ships within 1 business day · Discreet packaging
Questions about this material? Contact support@sealedpeptides.com
Specifications
| Stated purity | ≥99% (target) |
|---|---|
| Molecular Weight | 4731.3 Da |
| Molecular Formula | C221H342N46O68 |
| CAS Number | 2381089-83-2 |
| Compound Type | Triple Agonist |
| Form | Lyophilized powder |
| Sequence | Modified GLP-1/GIP/Glucagon receptor agonist |
| Half-Life | ~6 days |
| Storage | -20°C lyophilized; 2–8°C reconstituted |
| Reconstitution | Reconstitute with bacteriostatic water |
Research Notes
- Simultaneous activation of GLP-1, GIP, and glucagon receptors
- Phase 2 clinical studies have been published examining body-weight endpoints (see research overview)
- Glucagon receptor agonism is hypothesized to influence energy expenditure relative to dual agonists
Overview (Research Use Only)
Retatrutide is a triple incretin receptor agonist peptide supplied by Sealed Peptides for laboratory and research use only. This compound is designed to simultaneously engage GLP-1, GIP, and glucagon receptors.
This product is not intended for human consumption, clinical administration, or any diagnostic, therapeutic, or preventive use. All handling should follow institutional laboratory policies for research chemicals.
Research context
Preclinical and early clinical research has examined triple GLP-1/GIP/glucagon receptor agonism for metabolic and body composition endpoints. The glucagon receptor component distinguishes this class from dual agonists, with researchers hypothesizing enhanced energy expenditure effects. Published Published Phase 2 clinical studies have reported on body-weight endpoints in study populations.
Findings in clinical or preclinical systems do not establish safety or efficacy for any indication and must not be interpreted as medical claims.
Common questions
What does "research use only" mean?
This material is sold for laboratory and in-vitro research only. It is not for human or veterinary use, and we do not provide dosing guidance.
How should this vial be stored?
-20°C lyophilized; 2–8°C reconstituted
How fast does it ship?
Orders ship within 1 business day via USPS Priority Mail. Shipping is free on orders of $199.99 or more; otherwise it is $14.99. US only.
Who do I contact with questions about this product?
Email support@sealedpeptides.com with the product name and your question (include your order number if you have one).